Navigation Links
Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged
Date:4/22/2010

Experts dismiss need for long-term antibiotic therapy, but opponents call decision a 'rubber stamp',,

THURSDAY, April 22 (HealthDay News) -- After more than a year of study, a specially appointed panel at the Infectious Diseases Society of America has decided that controversial guidelines for the treatment of Lyme disease are correct and need not be changed.

The guidelines, first adopted in 2006, have long advocated for the short-term (less than a month) antibiotic treatment of new infections of Lyme disease, which is caused by Borrelia burgdorferi, a bacteria transmitted to humans via tick bites.

However, the guidelines have also been the focus of fierce opposition from certain patient advocate groups that believe there is a debilitating, "chronic" form of Lyme disease requiring much longer therapy.

The IDSA guidelines are important because doctors and insurance companies often follow them when making treatment (and treatment reimbursement) decisions.

The new review was sparked by an investigation launched by Connecticut Attorney General Richard Blumenthal, whose office had concerns about the process used to draft the guidelines.

"This was the first challenge to any of the infectious disease guidelines" the Society has issued over the years, IDSA president Dr. Richard Whitley said during a press conference held Thursday.

Whitley noted that the special panel was put together with an independent medical ethicist, Dr. Howard Brody, from the University of Texas Medical Branch, who was approved by Blumenthal so that the committee would be sure to have no conflicts of interest.

The guidelines contain 69 recommendations, Dr. Carol J. Baker, chair of the Review Panel, and pediatric infectious diseases specialist at Baylor College of Medicine, said during the press conference.

"For each of these recommendations our review panel found that each was medically and scientifically justified in light of all the evidence and information and required no revision," she said. For all but one of the votes the committee agreed unanimously, Baker added.

Particularly on the continued use of antibiotics, the panel had concerns that prolonged use of these drugs puts patients in danger of serious infection while not improving their condition, Baker said. "In the case of Lyme disease, there has yet to be a single high-quality clinical study that demonstrates comparable benefit to prolonging antibiotic therapy beyond one month," the panel members found.

As to the existence of a chronic, persistent form of Lyme disease, the panel concluded that "symptoms that are commonly attributed to chronic or persistent Lyme, such as arthralgias, fatigue and cognitive dysfunction, are seen in many other clinical conditions and are, in fact, common in the general population. It would thus be clinically imprudent to make the diagnosis of Lyme disease using these nonspecific findings alone."

Baker noted that so far there has been no comment from Attorney General Blumenthal on the panel's decision.

"I think the attorney general was misguided by the [Lyme disease] activists," Whitley said. "I do not think his contention against the Infectious Diseases Society was either justified or warranted," he added.

Whitley noted that the Society will be reviewing these guidelines again in another two years and at the same time the U.S. Institute of Medicine is working on its own report on the disease.

However, the committee's affirmation of the guidelines is seen by some to be a whitewash because, they claim, the review process was biased.

Dr. Robert Bransfield, president of the International Lyme and Associated Diseases Society, said: "How can there be such total consensus with any scientific issue? It's beyond comprehension."

Bransfield added, "It makes me wonder about the accuracy of the process. This is what everybody was expecting that they would do: a process that would rubber-stamp it and basically validate what was there before. It's a concern because it does compromise the best interest of patients."

Another critic, Dr. Raphael B. Stricker, a San Francisco physician who treats chronic Lyme disease, said that "when the panel votes eight-nothing on almost every single recommendation, that suggests that there is something wrong with the process.

"Until we get a really objective review by an objective panel that's not all in Infectious Diseases Society of America's pocket, you are going to get the kind of thing you see with this, and that's a problem," Stricker said.

On the other side of the issue, Phillip J. Baker, executive director of the American Lyme Disease Foundation, said he was pleased by the outcome.

"I have always felt, and so did many of my colleagues, that the guidelines are based on firm and established evidence," Baker said.

Baker has sympathy for people suffering from the pain and fatigue associated with chronic Lyme disease.

"These people are suffering from something and no doubt they need proper medical care," he said. "But they are not suffering from a persistent infection that can be treated by long-term antibiotic therapy. They have something serious that needs to be treated, but it's not due to Lyme disease."

More information

For more information on Lyme disease, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Phillip J. Baker, Ph.D., executive director, American Lyme Disease Foundation; Raphael B. Stricker, M.D., physician, San Francisco; Robert Bransfield, M.D., president, International Lyme and Associated Diseases Society; April 22, 2010, teleconference with: Richard Whitley, M.D., president, Infectious Diseases Society of America, Carol J. Baker, M.D., chair of the Review Panel, pediatric infectious diseases specialist at Baylor College of Medicine, Houston


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Review Spotlights Clues to Serious Childhood Infection
2. SIS Rules-Based Charging Solution Successfully Peer Reviewed by HFMA for Third Consecutive Year
3. Peer Review Experts Have Weighed In ... WEIGHLEVEL Is a Proven Winner
4. Review and approval of oncology and hematology drugs at FDA from 2005 to 2007
5. HCA Previews Fourth Quarter and Year-End 2009 Results
6. BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package
7. Hearing Aid Reviews Go Public on Advice on Hearing Aids
8. Webcast Alert: MicroRNA: The Year in Review
9. Beckman Coulter to Host Annual Business Review
10. Review Finds Marijuana May Help MS Patients
11. Review Questions Tamiflus Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology: